Form 4: Cytokinetics CEO Robert Blum Sells Shares to Cover Restricted Stock Unit Vesting

Cytokinetics CEO Robert Blum sold 16,970 shares of common stock on March 6, 2025, to cover taxes associated with the vesting of restricted stock units.

Summary

• On March 6, 2025, Robert I. Blum, President and CEO of Cytokinetics Inc., sold 16,970 shares of the company's common stock.
• The sale was executed at a price of $43.44 per share.
• This transaction was conducted to cover obligations related to the vesting of restricted stock units.
• Following the transaction, Blum directly owns 364,181 shares of Cytokinetics Inc.
• Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction related to executive compensation and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This is a routine Form 4 filing, which is common for executives who receive stock-based compensation. It provides transparency into insider transactions and is a normal part of corporate governance.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small percentage of the outstanding shares and is related to executive compensation.

Key Dates